ClinicalTrials.gg
Not yet recruitingNCT07623707Updated Jun 3, 2026

A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of FG-B901 and standard or investigator-determined chemotherapy in Solid Tumor, sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
264
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

FG-B901 is a recombinant humanized IgG2 bispecific antibody targeting PD-L1 and CD40. It is designed to provide PD-L1-dependent CD40 agonism, thereby enhancing selectivity for the tumor microenvironment and reducing systemic toxicity compared with conventional CD40 agonists. Preclinically, FG-B901 promotes antigen-presenting cell activation and synergizes with PD-L1/PD-1 blockade to potentiate T-cell anti-tumor immunity. This is an open-label, multicenter phase I/II trial in subjects with unresectable locally advanced or metastatic solid tumors. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of FG-B901 as monotherapy and in combination with chemotherapy. Secondary objectives include preliminary anti-tumor efficacy (e.g., objective response rate, disease control rate, progression-free survival, and overall survival).

02

Conditions studied

  • Solid Tumor

Keywords

  • CD40 agonist
03

In context

Lead sponsor

FutureGen Biopharmaceutical (Beijing) Co., Ltd is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily sign the form, understand the study, are willing to comply with and have the ability to complete all trial procedures;
  • Age 18-75 years (inclusive), any gender;
  • Have or cytologically confirmed locally advanced or solid tumors, and have failed standard therapy, or are intolerant to standard therapy, or for whom standard therapy is not available;
  • Able to provide tumor tissue specimens and peripheral blood samples that meet testing requirements, or provide prior test reports that meet the requirements;
  • performance status of 0 or 1;
  • Expected survival ≥3 months;
  • Have at least one measurable tumor lesion according to 1.1 criteria;
  • Adequate cardiac, bone marrow, liver, renal function;

Exclusion criteria

Exclusion Criteria:

  • Have received a within 3 months prior to randomization;
  • Have received radiotherapy within 4 weeks prior to randomization;
  • Have received other anti-tumor drug therapy within 4 weeks or within 5 half-lives of the anti-tumor drug prior to randomization;
  • Have undergone major surgery within 4 weeks prior to randomization;
  • Have received any clinical study drug treatment within 4 weeks prior to randomization;
  • Have undergone major surgery within 4 weeks prior to randomization;
  • Have a history of other (non-study tumor) within 3 years prior to randomization;
  • Have received any organ transplant or bone marrow transplant;
  • Have previously received any tumor necrosis factor receptor (TNFR) agonist antibody therapy, such as anti-0, anti-OX40, anti-CD137, anti-CD27, anti-CD357 antibodies, etc;
  • Have experienced Grade ≥3 immune-related adverse events (irAEs) from prior immunotherapy;
  • Have a history of severe allergic reactions or are allergic to the drug (FG-B901);
  • Have a history of central nervous system and/or carcinomatous meningitis;
  • Have adverse reactions from prior treatments that have not recovered to v5.0 Grade ≤1 (excluding alopecia and anemia) prior to randomization;
  • Have a history of severe respiratory disease;
  • Have experienced a cardiac disease within 6 months before the first dose of study drug;
  • Have uncontrolled systemic diseases assessed by the investigator, including diabetes, hypertension, pulmonary fibrosis, interstitial lung disease, etc.;
  • The investigator judges the subject to have obvious active gastrointestinal bleeding;
  • Known history of or chronic active ;
  • Have experienced systemic treatment with within ≤2 weeks prior to randomization;
  • Any other condition of the subject (e.g., psychological, geographical, or medical condition) that does not permit compliance with the study and follow-up procedures;
  • Are pregnant or breastfeeding;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation Cohort

    Nine dose levels of FG-B901 will be tested according to an accelerated titration method followed by a adaptive BOIN design.

    Drug: FG-B901

  • Experimental
    Monotherapy Dose Expansion Cohort

    Once the effective dose has been determined, 1\~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.

    Drug: FG-B901

  • Experimental
    Combined-therapy Dose Escalation Cohort

    Three dose levels of FG-B901 will be tested according to an accelerated titration method followed by a adaptive BOIN design.

    Drug: FG-B901 · Drug: standard or investigator-determined chemotherapy

  • Experimental
    Combined-therapy Dose Expansion Cohort

    Once the effective dose has been determined, 1\~2 expansion cohorts will be opened to evaluate the efficacy and safety of the selected dose.

    Drug: FG-B901 · Drug: standard or investigator-determined chemotherapy

Interventions

  • DrugFG-B901

    Accelerated titration method, IV infusion Q3W; Adaptive BOIN design, IV infusion Q3W. (21-day cycles)

  • Drugstandard or investigator-determined chemotherapy

    standard or investigator-determined chemotherapy depending on the type of tumors.

06

What researchers measure

Primary outcomes

  1. Safety assessed by Adverse Events (AEs)

    An AE is any adverse medical event that occurs during a clinical study, whether or not related with medicinal product, including signs, symptoms, abnormal laboratory test results and diseases. The incidence and severity of AEs during the clinical study are recorded and analyzed.

    Time frame: Up to 24 months

  2. Maximum Tolerated Dose (MTD)

    MTD

    Time frame: 21 days

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator evaluation per RECIST 1.1.

    Time frame: Up to 24 months

  2. Disease control rate (DCR)

    DCR is defined as the proportion of participants who have a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) as assessed by investigator evaluation per RECIST 1.1.

    Time frame: Up to 24 months

  3. Progression Free Survival (PFS)

    PFS is defined as the duration from randomization to the first imaging confirmation of progressive disease per RECIST 1.1 by investigator evaluation or death due to any cause (whichever occurs first).

    Time frame: Up to 24 months

  4. Duration Of Response (DOR)

    DOR is defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by investigator evaluation per RECIST 1.1 or death due to any cause (whichever occurs first).

    Time frame: Up to 24 months

  5. Overall Survival (OS)

    OS is defined as the time from randomization to deathdue to any cause.

    Time frame: Up to 24 months

  6. Maximum measured plasma concentration of FG-B901

    Cmax

    Time frame: Up to 24 months

  7. Time to maximum plasma concentration of FG-B901

    Tmax

    Time frame: Up to 24 months

  8. Half-life of FG-B901

    T1/2

    Time frame: Up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 3, 2026
StartEst.
Jul 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jul 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623707
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jul 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Zhaoyu Jin, Ph.D
Contact
pr@futuregenbiopharm.com
010-60709130

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion